Clinical Trial Search

Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05

Primary: Number of Participants With Any Grade 2 or Higher Event in the Injection Phase — 10; 75 Participants — p=<0.01

Primary: Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) AUC — 6.23; 24.1…

Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2

Primary: Incidence of Adjudicated Venous Thromboembolism (VTE) — 20; 15.4; 10 Percentage of Participants

Primary: Change in 18F-DTBZ Uptake in a Cohort of Parkinson's Disease Patients From Baseline to Month 36 — 12.95 SUVR

Primary: Cure of Bacterial Vaginosis — 33; 42; 11; 31 Participants

Primary: Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary — -0.1802; -0.1352; -0.1001 Proportion of days with pain

Primary: Annualized Relapse Rate — 0.45; 0.34 Relapse per year — p=0.3797

Primary: Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or Larger — 2; 2; 0 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 18; 14; 1; 1 participants

Primary: Number of Subjects With a Reduction in the Disease Activity Index of >3, or Clinical Remission. — 10; 0 Participants — p=0.03

Primary: Part A: Weighted Mean Change From Baseline in Pain Intensity Over the First 8 Hours Post-Dose Using VAS — -3.8; -47.4; -12.7 mm

Primary: Change From Baseline in Tinnitus Reaction on the Tinnitus Handicap Questionnaire Scores (0-100) at 4 Months — 22.03; 24.9; 23.7; 25.4 units on a scale — p=>0.05

Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants